STAT+: Gilead’s remdesivir sales are surging, but investors aren’t impressed

A lot more Covid-19 patients in the U.S. are being treated with Gilead's remdesivir because of the accelerating case counts. But even with sales of the medicine surging, investors are…

Click to view original post